Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says

Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says


An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Brendan McDermid | Reuters

All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug Administration’s drug shortage database on Friday. 

A previous update said some doses of the treatments were still in short supply. Some doses of Mounjaro have been in shortage since as early as 2022, while doses of Zepbound joined the FDA’s shortage list earlier this year following its U.S. approval in November. 

Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up manufacturing. 

The FDA’s update comes one day after Eli Lilly CEO David Ricks told Bloomberg that the shortages of Mounjaro and Zepbound would end “very soon.” 

“I think actually today or tomorrow we plan to exit that process,” he told the outlet in an interview. 

A spokesperson for Eli Lilly did not immediately respond to CNBC’s request for comment on the FDA’s update on Friday. 

All doses of Novo Nordisk’s diabetes injection Ozempic are available in the U.S. as of Friday, according to the FDA’s database. Meanwhile, the FDA said some doses of Novo Nordisk’s weight loss drug Wegovy have limited supply.

Don’t miss these insights from CNBC PRO



Source

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Health

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]

Read More
Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula
Health

Laura Modi, CEO and mom, is breaking one of the market’s biggest duopolies: Infant formula

Laura Modi, co-founder and CEO of infant formula startup Bobbie, is on a mission to transform an industry that she says has been stagnant for decades, and shift the culture around how parents feed their babies. Modi, a former Airbnb executive, came up with the idea for Bobbie after the birth of her first child. […]

Read More
Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
Health

Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers

U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with Pfizer to lower Medicaid drug prices in the Oval Office of the White House on September 30, 2025 in Washington, DC. Win Mcnamee | Getty Images President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not […]

Read More